Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Mullol, Joaquim" or (type any "bookEditor issueEditor" and editor="Mullol, Joaquim")

Add to list
- Journal Article
- A1
Dupilumab improves health-related quality of life in severe chronic rhinosinusitis with nasal polyps

Stella E Lee, Claire Hopkins, Joaquim Mullol, Jérôme Msihid, Isabelle Guillemin, Nikhil Amin, Leda P Mannent, Yongtao Li, Shahid Siddiqui and Asif H. Khan (UGent)

(2023) ALLERGY.
Add to list
- Journal Article
- A1
- open access
The unified airway hypothesis : evidence from specific intervention with anti–IL-5 biologic therapy

Claus Bachert (UGent) , Amber U. Luong, Philippe Gevaert (UGent) , Joaquim Mullol, Steven G. Smith, Jared Silver, Ana R. Sousa, Peter H. Howarth, Victoria S. Benson, Bhabita Mayer, et al.

(2023) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 11(9). p.2630-2641
Add to list
- Journal Article
European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis

Philippe Gevaert (UGent) , Jarno De Craemer, Claus Bachert (UGent) , Manon Blauwblomme (UGent) , Adam Chaker, Cemal Cingi, Peter W. Hellings, Claire Hopkins, Valérie Hox, Wytske J. Fokkens, et al.

(2023) Allergy. 78(4). p.912-922
Add to list
- Journal Article
- A1
- open access
Dupilumab improves health related quality of life : results from the phase 3 SINUS studies

Stella E Lee, Claire Hopkins, Joaquim Mullol, Jérôme Msihid, Isabelle Guillemin, Nikhil Amin, Leda P Mannent, Yongtao Li, Shahid Siddiqui, Chien Chia Chuang, et al.

(2022) ALLERGY. 77(7). p.2211-2221
Add to list
- Journal Article
- A1
- open access
Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID‐ERD : results from two randomized placebo‐controlled phase 3 trials

Joaquim Mullol, Tanya M. Laidlaw, Claus Bachert (UGent) , Leda P. Mannent, G. Walter Canonica, Joseph K. Han, Jorge F. Maspero, Cesar Picado, Nadia Daizadeh, Benjamin Ortiz, et al.

(2022) ALLERGY. 77(4). p.1231-1244
Add to list
- Conference Paper
- C3
Dupilumab leads to reduction of anosmia in patients with severe chronic rhinosinusitis with nasal polyps

Andrew Lane, Joaquim Mullol, Claire Hopkins, Wytske Fokkens, Stella Lee, Asif H. Khan (UGent) , Jérôme Msihid, Scott Nash, Shahid Siddiqui, Urvi Mujumdar, et al.

(2022) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 149(2). p.AB144-AB144
Add to list
- Journal Article
- A1
- open access
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study

Philippe Gevaert (UGent) , Rebecca Saenz, Jonathan Corren, Joseph K. Han, Joaquim Mullol, Stella E. Lee, Randall A. Ow, Rui Zhao, Monet Howard, Kit Wong, et al.

(2022) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 149(3). p.957-965.e3
Add to list
- Journal Article
- A1
- open access
Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps

Joaquim Mullol, Claus Bachert (UGent) , Nikhil Amin, Martin Desrosiers, Peter W Hellings, Joseph K Han, Roger Jankowski, Jan Vodicka, Philippe Gevaert (UGent) , Nadia Daizadeh, et al.

(2022) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 10(4). p.1086-1095.e5
Add to list
Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis Reply

Philippe Gevaert (UGent) , Jonathan Corren, Joaquim Mullol, Joseph Han, Stella E. Lee, Monica Ligueros-Saylan, Kit Wong, Theodore A. Omachi and Claus Bachert (UGent)

(2021) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 147(1). p.413-414
Add to list
Role of biologics in chronic rhinosinusitis with nasal polyposis : state of the art review

Christine Kim, Joseph Han, Tara Wu, Claus Bachert (UGent) , Wytske Fokkens, Peter Hellings (UGent) , Claire Hopkins, Stella Lee, Joaquim Mullol and Jivianne T. Lee

(2021) OTOLARYNGOLOGY-HEAD AND NECK SURGERY. 164(1). p.57-66

Academic Bibliography

Dupilumab improves health-related quality of life in severe chronic rhinosinusitis with nasal polyps

The unified airway hypothesis : evidence from specific intervention with anti–IL-5 biologic therapy

European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis

Dupilumab improves health related quality of life : results from the phase 3 SINUS studies

Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID‐ERD : results from two randomized placebo‐controlled phase 3 trials

Dupilumab leads to reduction of anosmia in patients with severe chronic rhinosinusitis with nasal polyps

Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study

Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps

Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis Reply

Role of biologics in chronic rhinosinusitis with nasal polyposis : state of the art review

Contents

Support

Contact